{"product_id":"generic-abemaciclib-abedx-2","title":"BESIDX (Abemaciclib)","description":"\u003cp\u003eAbemaciclib is used in combination with an aromatase inhibitor such as anastrozole (Arimidex), exemestane (Aromasin), or letrozole (Femara) to treat a certain type of hormone receptor-positive, early breast cancer. Abemaciclib is also used along with fulvestrant (Faslodex) to treat a certain type of hormone receptor-positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) or breast cancer that has spread to other parts of the body after treatment with an antiestrogen medication such as tamoxifen. Abemaciclib is also used along with anastrozole (Arimidex), exemestane (Aromasin), or letrozole (Femara) as a first treatment of hormone receptor-positive, advanced breast cancer or breast cancer that has spread to other parts of the body. Abemaciclib is also used alone to treat a certain type of hormone receptor-positive, advanced breast cancer or breast cancer that has spread to other parts of the body in people who have already been treated with an antiestrogen medication and chemotherapy. Abemaciclib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Early_Breast_Cancer\"\u003eEarly Breast Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, nodepositive, early breast cancer at high risk of recurrence\u003c\/p\u003e\u003cp\u003e150 mg PO BID PLUS tamoxifen or an aromatase inhibitor (see Prescribing Information)\u003c\/p\u003e\u003cp\u003eContinue for 2 years, or until disease recurrence or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Advanced_or_Metastatic_Breast_Cancer\"\u003eAdvanced or Metastatic Breast Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Monotherapy\"\u003eMonotherapy\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated as monotherapy for adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in metastatic setting\u003c\/li\u003e\n\u003cli\u003e200 mg PO BID\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Combination_therapy_with_aromatase_inhibitor\"\u003eCombination therapy with aromatase inhibitor\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with an aromatase inhibitor as initial endocrine-based therapy for HR-positive, HER2-negative advanced or metastatic breast cancer\u003c\/li\u003e\n\u003cli\u003e150 mg PO BID PLUS an aromatase inhibitor (see Prescribing Information)\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Combination_therapy_with_fulvestrant\"\u003eCombination therapy with fulvestrant\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated, in combination with fulvestrant, for adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy\u003c\/li\u003e\n\u003cli\u003e150 mg PO BID PLUS\u003c\/li\u003e\n\u003cli\u003eFulvestrant 500 mg IM on Days 1, 15, and 29, and then once monthly thereafter\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Dosage_modifications_for_adverse_effects\"\u003eDosage modifications for adverse effects\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Combined_with_fulvestrant_tamoxifen_or_aromatase_inhibitor\"\u003eCombined with fulvestrant, tamoxifen, or aromatase inhibitor\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eStarting dose: 150 mg BID\u003c\/li\u003e\n\u003cli\u003eFirst dose reduction: 100 mg BID\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 50 mg BID\u003c\/li\u003e\n\u003cli\u003eDiscontinue if unable to tolerate 50 mg BID\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Monotherapy1\"\u003eMonotherapy\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eStarting dose: 200 mg BID\u003c\/li\u003e\n\u003cli\u003eFirst dose reduction: 150 mg BID\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 100 mg BID\u003c\/li\u003e\n\u003cli\u003eThird dose reduction: 50 mg BID\u003c\/li\u003e\n\u003cli\u003eDiscontinue if unable to tolerate 50 mg BID\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797949607979,"sku":"RL1820240701","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-06-2439.jpg?v=1787022132","url":"https:\/\/xomeds.com\/products\/generic-abemaciclib-abedx-2","provider":"XOMEDS","version":"1.0","type":"link"}